WST - West Pharmaceutical Services Inc Stock Price, Fair Value and News

385.82USD-4.38 (-1.12%)Market Closed

Market Summary

USD385.82-4.38

Market Closed

-1.12%

WST Stock Price

View Fullscreen

WST RSI Chart

WST Valuation

Market Cap

28.6B

Price/Earnings (Trailing)

48.2

Price/Sales (Trailing)

9.7

EV/EBITDA

33.09

Price/Free Cashflow

WST Price/Sales (Trailing)

WST Profitability

EBT Margin

23.66%

Return on Equity

20.6%

Return on Assets

15.5%

Free Cashflow Yield

1.45%

WST Fundamentals

WST Revenue

Revenue (TTM)

2.9B

Rev. Growth (Yr)

3.29%

Rev. Growth (Qtr)

-2.06%

WST Earnings

Earnings (TTM)

593.4M

Earnings Growth (Yr)

33.01%

Earnings Growth (Qtr)

-15.07%

Breaking Down WST Revenue

Last 7 days

2.8%

Last 30 days

-0.9%

Last 90 days

11.9%

Trailing 12 Months

5.0%

How does WST drawdown profile look like?

WST Financial Health

Current Ratio

2.88

Debt/Equity

0.03

Debt/Cashflow

10.67

WST Investor Care

Dividend Yield

0.2%

Dividend/Share (TTM)

0.78

Buy Backs (1Y)

1.13%

Diluted EPS (TTM)

7.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.9B	2.9B	2.9B	2.9B
2022	2.9B	2.9B	2.9B	2.9B
2021	2.3B	2.5B	2.7B	2.8B
2020	1.9B	1.9B	2.0B	2.1B
2019	1.7B	1.8B	1.8B	1.8B
2018	1.6B	1.7B	1.7B	1.7B
2017	1.5B	1.5B	1.6B	1.6B
2016	1.4B	1.5B	1.5B	1.5B
2015	1.4B	1.4B	1.4B	1.4B
2014	1.4B	1.4B	1.4B	1.4B
2013	1.3B	1.3B	1.3B	1.4B
2012	1.2B	1.2B	1.2B	1.3B
2011	1.1B	1.2B	1.2B	1.2B
2010	1.1B	1.1B	1.1B	1.1B
2009	0	1.1B	1.1B	1.1B
2008	0	0	0	1.1B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of West Pharmaceutical Services Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	winters chad	acquired	116,924	173	675	vp, chief accounting officer
Mar 11, 2024	winters chad	sold	-292,436	358	-815	vp, chief accounting officer
Feb 28, 2024	witherspoon charles	acquired	206,968	102	2,019	vp & treasurer
Feb 28, 2024	witherspoon charles	sold	-724,061	358	-2,019	vp & treasurer
Feb 27, 2024	green eric mark	sold	-23,078,000	359	-64,132	president, ceo and board chair
Feb 27, 2024	green eric mark	acquired	4,196,310	57.38	73,132	president, ceo and board chair
Feb 23, 2024	abraham silji	acquired	1,214,620	173	7,012	svp, chief technology officer
Feb 23, 2024	abraham silji	sold	-2,559,380	365	-7,012	svp, chief technology officer
Feb 20, 2024	abraham silji	acquired	-	-	646	svp, chief technology officer
Feb 20, 2024	winters chad	acquired	-	-	179	vp, chief accounting officer

Which funds bought or sold WST recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Revisor Wealth Management LLC	added	98.81	297,001	564,260	0.26%
Apr 23, 2024	Venturi Wealth Management, LLC	reduced	-1.89	105,061	1,131,160	0.07%
Apr 23, 2024	Bell Bank	reduced	-10.07	18,961	1,811,960	0.16%
Apr 23, 2024	Louisiana State Employees Retirement System	reduced	-4.44	117,013	1,701,550	0.03%
Apr 23, 2024	CARDEROCK CAPITAL MANAGEMENT INC	added	50.57	3,176,230	7,765,410	2.18%
Apr 23, 2024	AMALGAMATED BANK	reduced	-19.82	-699,000	6,364,000	0.05%
Apr 23, 2024	FIFTH THIRD BANCORP	added	1.9	509,382	4,020,020	0.02%
Apr 23, 2024	KLR INVESTMENT ADVISORS, LLC	reduced	-6.67	-3,006	577,288	0.42%
Apr 23, 2024	CIGNA INVESTMENTS INC /NEW	unchanged	-	34,000	311,000	0.06%
Apr 23, 2024	NEW MEXICO EDUCATIONAL RETIREMENT BOARD	reduced	-5.13	91,000	1,464,000	0.05%

Are Funds Buying or Selling WST?

Are funds buying WST calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own WST

No. of Funds

Unveiling West Pharmaceutical Services Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	12.17%	9,002,632	SC 13G/A
Jan 24, 2024	blackrock inc.	10.5%	7,778,203	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	3.1%	2,301,161	SC 13G/A
Feb 09, 2023	vanguard group inc	12.14%	8,988,409	SC 13G/A
Jan 24, 2023	blackrock inc.	11.0%	8,148,624	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	8.4%	6,241,901	SC 13G/A
Feb 04, 2022	franklin resources inc	3.8%	2,848,869	SC 13G/A
Jan 27, 2022	blackrock inc.	10.9%	8,094,288	SC 13G/A
Jan 25, 2022	blackrock inc.	10.9%	8,094,288	SC 13G/A
Apr 12, 2021	blackrock inc.	10.1%	7,467,809	SC 13G/A

Recent SEC filings of West Pharmaceutical Services Inc

View All Filings

Date Filed	Form Type	Document
Mar 19, 2024	PX14A6G	PX14A6G
Mar 13, 2024	ARS	ARS
Mar 13, 2024	DEF 14A	DEF 14A
Mar 13, 2024	DEFA14A	DEFA14A
Mar 12, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading
Mar 01, 2024	PRE 14A	PRE 14A
Feb 29, 2024	4	Insider Trading
Feb 27, 2024	144	Notice of Insider Sale Intent
Feb 27, 2024	4	Insider Trading

Peers (Alternatives to West Pharmaceutical Services Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.7B	40.1B	-2.69%	-2.54%	32.62	4.65	-8.12%	-17.45%
BDX	67.7B	19.5B	-4.86%	-10.59%	53.89	3.47	4.02%	-22.04%
ALGN	23.4B	3.9B	-2.36%	-14.10%	52.63	6.06	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.84	1.41	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.48	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.02%	16.40%	32.52	2.65	4.97%	18.89%
BIO	8.3B	2.7B	-18.63%	-38.25%	-13.07	3.12	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.58	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-558.61	9.25	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.02	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	383.0M	166.7M	1.30%	-3.37%	-4.63	2.3	6.67%	-456.34%
ANGO	241.5M	324.0M	12.50%	-31.24%	-1.26	0.75	-3.19%	-337.41%
APYX	45.7M	52.3M	5.60%	-56.15%	-2.44	0.87	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.32	1.06	5.77%	8.23%

West Pharmaceutical Services Inc News

Latest updates

West Pharmaceutical Services Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-2.1%	732	747	754	717	709	687	771	720	731	707	724	671	580	548	527	492	471	456	470	444	423
Gross Profit	-3.5%	278	288	291	271	262	268	322	285	301	288	315	272	211	195	195	167	153	148	158	147	133
S&GA Expenses	1.1%	90.00	89.00	88.00	86.00	86.00	66.00	82.00	83.00	98.00	92.00	93.00	80.00	76.00	76.00	78.00	72.00	69.00	65.00	70.00	69.00	60.00
R&D Expenses	12.2%	18.00	16.00	17.00	17.00	16.00	14.00	14.00	15.00	14.00	13.00	14.00	12.00	13.00	13.00	11.00	11.00	10.00	9.00	10.00	10.00	10.00
EBITDA Margin	4.6%	0.29*	0.27*	0.26*	0.27*	0.28*	0.30*	0.31*	0.31*	0.31*	0.30*	0.28*	0.26*	0.24*	-	-	-	-	-	-	-	-
Interest Expenses	-58.6%	1.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Income Taxes	17.3%	35.00	29.00	35.00	24.00	29.00	20.00	44.00	21.00	34.00	12.00	32.00	29.00	20.00	21.00	16.00	15.00	17.00	11.00	16.00	16.00	15.00
Earnings Before Taxes	-10.1%	168	187	185	158	129	136	227	188	182	181	211	175	115	98.00	102	87.00	77.00	65.00	80.00	70.00	66.00
EBT Margin	5.2%	0.24*	0.23*	0.21*	0.23*	0.24*	0.25*	0.27*	0.26*	0.26*	0.25*	0.24*	0.21*	0.19*	-	-	-	-	-	-	-	-
Net Income	-15.1%	137	161	155	140	103	121	189	174	148	176	187	151	98.00	82.00	91.00	74.00	64.00	56.00	66.00	55.00	52.00
Net Income Margin	5.2%	0.20*	0.19*	0.18*	0.19*	0.20*	0.22*	0.23*	0.24*	0.23*	0.23*	0.21*	0.18*	0.16*	-	-	-	-	-	-	-	-
Free Cashflow	-2.9%	130	134	94.00	56.00	136	111	107	85.00	84.00	125	88.00	34.00	91.00	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	2.0%	3,830	3,755	3,670	3,724	3,617	3,317	3,362	3,295	3,314	3,143	2,934	2,740	2,794	2,583	2,392	2,247	2,341	2,174	2,123	2,036	1,979
Current Assets	-1.8%	1,936	1,972	1,874	1,937	1,920	1,734	1,771	1,691	1,742	1,598	1,477	1,327	1,374	1,238	1,111	978	1,059	1,004	944	868	894
Cash Equivalents	-5.0%	854	899	796	886	894	729	719	668	763	688	576	484	616	519	446	335	439	396	327	266	337
Inventory	0.7%	435	432	449	447	415	413	412	417	378	354	345	310	321	295	275	251	236	230	232	226	215
Net PPE	7.8%	1,413	1,312	1,261	1,215	1,158	1,069	1,077	1,066	1,058	1,007	973	931	943	883	840	828	839	812	823	815	822
Goodwill	1.6%	109	107	108	108	107	104	107	109	110	109	110	110	111	109	108	107	108	107	108	105	106
Liabilities	7.0%	949	887	923	947	932	846	937	969	978	940	901	911	939	864	786	756	768	686	678	667	583
Current Liabilities	25.9%	672	534	512	535	519	457	565	585	594	559	473	483	503	448	375	344	342	335	313	301	284
Long Term Debt	-52.1%	73.00	152	206	206	207	207	208	208	209	210	252	252	253	253	254	254	255	195	196	196	196
LT Debt, Non Current	-52.1%	73.00	152	206	206	207	207	208	208	209	210	252	252	253	253	254	254	255	195	196	196	196
Shareholder's Equity	0.4%	2,881	2,868	2,747	2,776	2,685	2,471	2,424	2,326	2,335	2,202	2,033	1,829	1,855	1,719	1,606	1,490	1,573	1,488	1,445	1,370	1,396
Retained Earnings	3.1%	3,523	3,416	3,255	3,114	2,988	2,913	2,793	2,617	2,457	2,336	2,160	1,985	1,847	1,773	1,703	1,612	1,549	1,497	1,453	1,398	1,353
Additional Paid-In Capital	-2.0%	120	123	158	181	232	231	225	220	249	251	248	247	267	268	263	268	273	269	273	279	282
Accumulated Depreciation	2.3%	1,325	1,296	1,282	1,264	1,228	1,164	1,169	1,171	1,158	1,140	1,125	1,098	1,092	1,056	1,018	989	981	968	964	945	931
Shares Outstanding	-0.7%	74.00	74.00	74.00	74.00	74.00	74.00	74.00	74.00	74.00	74.00	74.00	74.00	74.00	-	-	-	-	-	-	-	-
Float	-	-	-	28,200	-	-	-	22,300	-	-	-	26,500	-	-	-	16,742	-	-	-	9,218	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	3.9%	239,100	230,100	169,200	138,100	230,800	168,900	173,100	151,200	160,800	190,100	144,400	88,700	148,700	118,600	148,100	57,100	106,400	108,100	105,100	47,600	73,200
Share Based Compensation	-76.3%	1,400	5,900	7,500	8,500	6,700	6,000	5,500	5,500	9,950	11,400	10,300	5,900	6,350	10,000	12,300	5,400	5,600	5,400	7,200	6,200	400
Cashflow From Investing	-13.7%	-108,800	-95,700	-82,100	-82,100	-94,800	-59,100	-66,000	-68,300	-77,400	-65,300	-55,900	-54,500	-57,600	-49,100	-40,900	-31,900	-120,600	-31,600	-47,100	-28,700	-28,600
Cashflow From Financing	-749.8%	-189,500	-22,300	-176,800	-71,000	-9,500	-75,200	-36,200	-172,700	-6,200	-5,800	300	-156,400	-8,700	-7,200	-900	-120,300	51,000	-400	3,100	-90,500	-8,200
Dividend Payments	5.7%	14,800	14,000	14,100	14,100	14,100	13,500	13,100	13,400	13,300	12,600	12,600	12,600	12,600	11,900	11,800	11,800	11,800	11,100	11,100	11,100	11,100
Buy Backs	536.7%	177,000	27,800	173,400	60,100	-100	27,200	28,600	147,100	-	-	-	137,100	-	-	-	115,500	-	-	-	83,100	-

WST Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net sales	$ 2,949.8	$ 2,886.9	$ 2,831.6
Cost of goods and services sold	1,820.6	1,750.7	1,655.8
Gross profit	1,129.2	1,136.2	1,175.8
Research and development	68.4	58.5	52.8
Selling, general and administrative expenses	353.4	316.9	362.8
Other expense (income) (Note 16)	31.4	26.8	7.9
Operating profit	676.0	734.0	752.3
Interest expense	9.0	7.9	8.2
Interest income	(28.0)	(5.1)	(1.0)
Other nonoperating (income) expense	(3.0)	51.3	(3.8)
Income before income taxes and equity in net income of affiliated companies	698.0	679.9	748.9
Income tax expense	122.3	114.7	107.2
Equity in net income of affiliated companies	(17.7)	(20.7)	(20.1)
Net income	$ 593.4	$ 585.9	$ 661.8
Net income per share:
Basic (in dollars per share)	$ 7.98	$ 7.87	$ 8.89
Diluted (in dollars per share)	$ 7.88	$ 7.73	$ 8.67
Weighted average shares outstanding:
Basic (in shares)	74.3	74.4	74.4
Diluted (in shares)	75.3	75.8	76.3

WST Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 853.9	$ 894.3
Accounts receivable, net	512.0	507.4
Inventories	434.7	414.8
Other current assets	135.8	103.0
Total current assets	1,936.4	1,919.5
Property, plant and equipment	2,738.0	2,386.6
Less: accumulated depreciation and amortization	1,324.7	1,228.3
Property, plant and equipment, net	1,413.3	1,158.3
Operating lease right-of-use assets	99.2	104.4
Investments in affiliated companies	210.0	204.9
Goodwill	108.5	107.3
Intangible assets, net	15.1	18.4
Deferred income taxes	25.7	65.6
Other noncurrent assets	21.3	38.4
Total Assets	3,829.5	3,616.8
Current liabilities:
Notes payable and other current debt	134.0	2.2
Accounts payable	242.4	215.4
Accrued salaries, wages and benefits	105.9	76.8
Income taxes payable	16.6	24.8
Operating lease liabilities	17.7	16.0
Other current liabilities	155.2	183.8
Total current liabilities	671.8	519.0
Long-term debt	72.8	206.7
Deferred income taxes	12.7	14.3
Pension and other postretirement benefits	29.6	28.2
Operating lease liabilities	84.5	93.0
Deferred compensation benefits	18.6	19.1
Other long-term liabilities	58.5	51.6
Total Liabilities	948.5	931.9
Commitments and contingencies (Note 18)
Equity:
Preferred stock, 3.0 million shares authorized; 0.0 shares issued and outstanding in 2023 and 2022	0.0	0.0
Common stock, par value $0.25 per share; 200 million shares authorized; shares issued: 75.3 million in 2023 and 2022; shares outstanding: 73.5 million and 74.1 million in 2023 and 2022	18.8	18.8
Capital in excess of par value	120.2	232.2
Retained earnings	3,523.4	2,987.8
Accumulated other comprehensive loss	(143.8)	(183.0)
Treasury stock, at cost (1.8 million and 1.2 million shares in 2023 and 2022)	(637.6)	(370.9)
Total Equity	2,881.0	2,684.9
Total Liabilities and Equity	$ 3,829.5	$ 3,616.8

About West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

CEO	Mr. Eric M. Green
WEBSITE	westpharma.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	10700

West Pharmaceutical Services Inc Frequently Asked Questions

What is the ticker symbol for West Pharmaceutical Services Inc? What does WST stand for in stocks?

WST is the stock ticker symbol of West Pharmaceutical Services Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of West Pharmaceutical Services Inc (WST)?

As of Tue Apr 23 2024, market cap of West Pharmaceutical Services Inc is 28.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of WST stock?

You can check WST's fair value in chart for subscribers.

What is the fair value of WST stock?

You can check WST's fair value in chart for subscribers. The fair value of West Pharmaceutical Services Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of West Pharmaceutical Services Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for WST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is West Pharmaceutical Services Inc a good stock to buy?

The fair value guage provides a quick view whether WST is over valued or under valued. Whether West Pharmaceutical Services Inc is cheap or expensive depends on the assumptions which impact West Pharmaceutical Services Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for WST.

What is West Pharmaceutical Services Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, WST's PE ratio (Price to Earnings) is 48.2 and Price to Sales (PS) ratio is 9.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. WST PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on West Pharmaceutical Services Inc's stock?

In the past 10 years, West Pharmaceutical Services Inc has provided 0.255 (multiply by 100 for percentage) rate of return.